Increased study participation is key to the improvement in pancreatic cancer survival

2012 01 12Increasing patient participation in clinical trials is essential if new treatments are to be developed that can improve the current prognosis for pancreatic cancer, which is a five-year relative survival rate of just 6%, notes the Pancreatic Cancer Action Network.

The lack of available treatment options for pancreatic cancer means enrolment in clinical trials is critical for both current and future patients, the Network says.

Presently, only three FDA approved drugs are available to treat pancreatic adenocarcinoma, the most common form of pancreatic cancer and the Network recommends that all patients consider clinical trials when exploring treatment options.

For more information see:

Comments are closed.